Heparin - Disruption Risk Intelligence, Edition 1

Michael Griffin

— 5 min read
Share
VEROLYX
Cross-Sector Disruption Intelligence
Heparin
Disruption Risk Intelligence — Edition 1
July 2026
1
AT A GLANCE
Critical

Heparin is a widely used anti-coagulant essential to cardiovascular surgery, dialysis, and clot prevention, making it a critical care drug with no easy substitute at scale. Demand is driven by rising surgical volumes and cardiovascular disease burden, with production heavily concentrated on porcine intestinal mucosa sourced primarily from China. This concentration in China was exposed in 2008 as a serious single point of failure, which continues to shape how regulators and manufacturers invest in supply chain resilience for access to this drug today.

KEY TREND INDICATORS
SUPPLY SHOCK TRIGGER African Swine Fever in China, India, Sri Lanka, Poland, and Germany
What is happening Heparin sodium injection is a currently active, FDA-listed drug shortage across multiple manufacturers (Apr–May 2026), per US federal government document and peer-reviewed literature. This is due to lingering effects of African Swine Fever on China's pig population, which is the source of 80% of the world's heparin raw material.
Why it matters beyond heparin A clear and current supply-side trigger: an animal-health event impacting a raw material base's availability, independent of any human demand shock.
What to watch next It is unclear whether enoxaparin and fondaparinux — both already constrained fallback options — will stabilize or tighten further, and whether China-specific 2026 herd data (not yet in open sources) will clarify how much of the current shortage is new versus lingering from 2019.

Subscribe to Verolyx Pro to unlock the full disruption analysis: the risk classification, the four-layer value chain assessment, the composite instability scoring, the final assessment, and full source annex for this edition.

2
TYPE OF RISK
Supply Side Trigger

Heparin's classification is a Supply Shock Trigger: African Swine Fever is depleting an existing raw material supply, independent of any change in demand for heparin itself. It is not a Demand Trigger (no human disease event is pulling on heparin demand), not a Structural Scarcity Trigger (heparin has multiple manufacturers, not a single source), and not a Natural Disaster Trigger (ASF is an animal disease event, not a geophysical one).

3
Market Evidence
Value Chain Overview

Heparin's value chain is short but extremely narrow at its origin. Unlike a typical industrial material, its starting point is a byproduct of an entirely different industry, pork production. This sets a hard ceiling on how much raw material can ever exist, independent of anything happening in the pharmaceutical industry itself.

1. CROSS-SECTOR DEMAND LAYER

Heparin's cross-sector dimension runs through its shared upstream raw material of porcine intestinal mucosa. This feedstock, via the same abattoir supply chains, supplies gelatin and other porcine byproducts. Thus, any African Swine Fever outbreak could collapse the raw material markets across several biological-input industries simultaneously, not just heparin.

  • Market Scale: Estimates vary — roughly $5.8B to $10B in 2025.
  • Product Mix: LMWH holds ~63% of revenue share; enoxaparin is also experiencing 2026 disruptions.
  • Baseline demand drivers: Cardiovascular disease prevalence, rising surgical/dialysis volumes, aging population, heparin-coated devices.

Assessment: An intensification of the shortage and there may be a multi-sector shortage.

2. VALUE CHAIN VULNERABILITY LAYER

Heparin's exposure to chokepoints in the supply chain centre around the concentration of raw material sourcing, regulations, and diversification efforts.

  • Concentration: ~80% of global heparin API volumes originate in China.
  • Regulations: FDA historically permitted only porcine-derived heparin; now encouraging bovine-sourced diversification.
  • Emerging mitigation: Synthetic/biosynthetic (E. coli-based) production is in early stage scale-up, not yet a structural fix.

Assessment: One country, one species, one regulator's rulebook. Heparin's whole supply chain balances on a single point of failure.

3. TRIGGER LAYER

African Swine Fever is not a historically closed case. It is an active, worsening multi-country event as of mid-2026. FAO's EMPRES-AH June 2026 update reports ASF actively spreading across 20 countries and territories in Asia-Pacific, including fresh outbreaks in India (22 of 28 states plus the NCT), continued devastation in Sri Lanka's pig sector, and new cases in Nagaland, Assam, and Meghalaya (May–June 2026). Europe is also impacted — Poland's first domestic-pig ASF outbreak of 2026 (21,000+ pigs), and a re-emergence in Saxony, Germany, after previously achieving disease-free status. New reassortant ASF strains have been confirmed moving via traveler-carried pork products, per Chinese border screening.

Assessment: A seven-year-old outbreak still spreading, still mutating, and still no end in sight. Worse than 2019's near-miss, not yet 2008's catastrophe — the conditions for a repeat haven't gone away.

4. COMPETITIVE / STRUCTURAL LAYER

This layer names factors that have nothing to do epidemiologically or zoonotically. Because heparin is a secondary claimant on a food-industry byproduct, the total availability of raw material is set primarily by global pork consumption and slaughter volume, not by heparin demand by itself. A shift in pork consumption could tighten heparin markets, compounding the supply shock vulnerabilities.

Assessment: Heparin isn't just vulnerable to disease of pigs; it is vulnerable to food consumption.

4   COMPOSITE INSTABILITY SCORING

Each tracked material or product receives a composite instability score built from five independently scored dimensions. The composite is not a precise probability estimate, but a structured, comparable severity read. Composite is analyst-assigned against methodology's rubric, using public data — not an automated statistical model.

Dimension Severity Trend / Evidence
Signal Trajectory
Is the signal accelerating, steady, or resolving?		 HIGH ASF actively spreading across 20 countries. Not contained or resolved.
Concentration Risk
How few independent points of failure exist?		 HIGH ~80% of global API from one country.
Substitutability
Does a realistic, unconstrained alternative exist?		 HIGH Both alternatives (enoxaparin and fondaparinux) are also constrained.
Time to Impact
How much lead-time buffer exists?		 IMMEDIATE Already a confirmed, current FDA-listed shortage.
Precedent Frequency
Has this pattern occurred before, and how often?		 HIGH Two significant precedents tied to the same root fragility (2008, 2018–2021).
5
FINAL ASSESSMENT
Critical

Every scored dimension aligns as HIGH. This reflects a confirmed active shortage due to a continued Trigger of African Swine Fever. Additionally, there are structural issues in the markets including lack of geographical diversification of raw material feedstock (80% of raw feedstock is in China), and constrained alternatives.

KEY TAKEAWAYS
  • Heparin continues to experience a supply-side trigger after experiencing a breakout of African Swine Fever in China 7 years ago.
  • Current global supply for heparin will continue to be stressed due to reliance on the Chinese pig population. Alternatives, enoxaparin and fondaparinux, are also experiencing shortages.
  • No relationship to other tracked materials or stakeholders in the value chain is asserted — though heparin's own chain carries real cross-industry exposure through shared porcine byproducts such as gelatin.
A
ANNEX — Notes
  • No official FDA or EMA statement was found directly and explicitly naming African Swine Fever as the cause of the current 2026 heparin shortage for every affected product — the linkage rests on the Dept. of Commerce document, the peer-reviewed RPTH piece, and the Miga Solutions advisory, not a single unified regulatory statement.
  • China's current (2026) pig herd status specific to renewed or lingering ASF impact was not directly found — the report's causal chain should be explicit that it is China's herd status specifically that matters most for heparin.
  • No quantified crude heparin or API spot-price series for 2025–2026 was found — this report relies on shortage-listing/availability status rather than price data.
  • The pork-consumption Competitive/Structural layer is not yet backed by a dedicated search — flagged as an open item rather than presented as sourced.
B
ANNEX — Sources

Pharma Manufacturing (13 Nov 2019); UPI (1 May 2019); Fierce Pharma (2 Sep 2019); Seattle Times (3 Sep 2019); The Medicine Maker (25 Sep 2019); FDA Drug Shortages database; Drugs.com and ASHP/University of Utah Drug Shortage Bulletins (2026); Miga Solutions supply-chain advisory (March 2026); Medfinder shortage-tracking briefings on enoxaparin and fondaparinux (2026); U.S. Department of Commerce, Bureau of Industry and Security (6 May 2025); "Worldwide Heparin Shortage," Research and Practice in Thrombosis and Haemostasis (May 2025); FDA, "FDA Encourages Reintroduction of Bovine-Sourced Heparin"; Journal of Thrombosis and Haemostasis / Vilanova et al. (2019); The Lancet, "Running thin: implications of a heparin shortage" (2020); Pharmaceutical Executive (20 May 2026); FAO EMPRES-AH African Swine Fever situation updates, Asia & Pacific (June 2026); Global Biodefense (18 June 2026); Swine Health Information Center Global Disease Monitoring Reports; USDA Economic Research Service; American Farm Bureau Federation Market Intel; WOAH; drug-dev.com and PharmTech; PDA Letter; Global Market Insights, Mordor Intelligence, and other market-sizing vendors (2025–2026, figures vary by methodology).

Read more